ENTBF News and Press, Entheon Biomedical Corp Com From 11/10/21

Entheon Biomedical (OTCQB:ENTBF) announces that recruitment has begun for the clinical research study with Heading Health to determine the electro-neurophysiologic effects of ketamine. EBIQ-101, an Open Label Observational Study, will observe the EEG pattern of participants being treated...

Entheon ID(TM) Clinical Study to Assess the Effect of Ketamine on Neurological Activity as Measured by EEG Vancouver, British Columbia--(Newsfile Corp. - November 10, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biotechnology comp...

Addiction is an issue that affects a significant number of people worldwide. While conventional treatments have existed for decades, they offer a very low rate of efficacy, often as low as 5%. For Timothy Ko, CEO of Entheon Biomedical , the problem is personal, and he’...

Vancouver, British Columbia--(Newsfile Corp. - October 27, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to provide an update on its op...

Toronto, Ontario--(Newsfile Corp. - September 23, 2021) - Microdose Psychedelic Insights is proud to announce the upcoming Psychedelic Capital: September 2021 conference to be taking place on September 30, 2021, starting at 1:30pm EDT. The September edition will engage in discussions on Nov...

Microdose Psychedelic Insights will host the upcoming DMT Conference on September 9-10th, 2021 Part of a series of deep dive events looking into various psychoactive and psychedelic substances, the DMT conference will examine the potential of DMT within today’s society The conf...

NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- via NetworkNewsWire -- Microdose Psychedelic Insights , a cutting-edge media company focused on promoting content, financial analysis, and engaging events designed to drive the psychedelics industry into the forefront of modern medicine, w...

Dr. David Erritzoe to provide guidance on psychopharmacological research Vancouver, British Columbia--(Newsfile Corp. - August 25, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biotechnology company focused on developing psychedeli...

Vancouver, British Columbia--(Newsfile Corp. - August 24, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that its common sha...

EEG Study to be incorporated into Entheon IQ(TM), developing data-driven treatment algorithms for psychedelic treatments Vancouver, British Columbia--(Newsfile Corp. - August 12, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biotec...